Clinical trial NCT01025570: A Study Evaluating Gemcitabine Plus Bosutinib for Patients With Resected Pancreatic Cancer
Official title: A Study Evaluating Safety and Efficacy of Gemcitabine Plus Bosutinib for Patients With Resected Pancreatic Adenocarcinoma
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
Conditions: Pancreatic Cancer
Keywords: pancreas
pancreatic
bosutinib
SKI-606
gemcitabine
gemzar
Patients with resected pancreatic cancer
Lead sponsor: University of California, San Francisco
Sponsor class: OTHER
Collaborators: name: University of Utah
First posted: 2009-12-03
Enrollment: 3
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to find out the effects, good and/or bad, of the combination of two drugs, gemcitabine and bosutinib, in patients with resected pancreatic cancer and whether this combination can prevent pancreatic cancer from coming back.


Eligibility criteria: Inclusion Criteria:

* Histologically proven adenocarcinoma of the pancreas.
* Complete resection by standard pancreaticoduodenectomy (for tumors of the pancreatic head) or distal pancreatectomy (for tumors of the pancreatic tail). Positive microscopic margins are allowable.
* No measurable disease.
* ECOG performance status 0 - 1.
* ≥ 18 years of age.
* Ability to start adjuvant therapy within 8 weeks after pancreatic cancer surgery (but no sooner than 3 weeks).
* CA 19-9 ≤ 2.5 times the upper limit of normal.
* ANC (absolute neutrophil count) ≥ 1500/μL
* Hemoglobin ≥ 9 gm/dL (may be transfused or may receive epoetin alfa to maintain this level)
* Platelet count ≥ 100,000/μL
* INR ≤ 1.5 (except those subjects who are receiving full-dose warfarin)
* Total bilirubin ≤ 2.0 mg/dL
* AST and ALT ≤ 2.5 times the upper limit of normal
* Serum creatinine ≤ 2.0
* Negative pregnancy test for women of childbearing potential (serum or urine beta-HCG).
* All patients must be informed of the investigational nature of this study and sign and give written informed consent in accordance with institutional and federal guidelines.
* Women or men of reproductive potential must agree to use an effective contraceptive method during treatment and for 6 months afterwards.
* At least one paraffin block from patient's pancreatic cancer surgery must be available for analysis (does not necessarily need to be received by the start of study treatment).

Exclusion Criteria:

* Any prior systemic or investigational therapy for pancreatic cancer.
* Grossly positive surgical margins.
* Any of the following post-operative complications: wound dehiscence or infection, intraabdominal abscess, pancreatic or biliary leak or fistula.
* History of major psychiatric disorder or other chronic medical illness that, in the opinion of the treating physician, contraindicates the use of the investigational drugs in this protocol or that might render the subject at high risk of treatment related complications.
* Serious active ongoing infection, including any requiring parenteral antibiotics.
* Patients with a "currently active" second malignancy other than non-melanoma skin cancer. Patients are not considered to have a "currently active" malignancy if they have completed therapy and considered by their physician to be at less than 30% risk of relapse.
* Pregnancy (positive pregnancy test) or lactation.
* Known central nervous system disease.
* Inability to swallow pills/tolerate oral intake.
* Inability to comply with study and/or follow-up procedures.

Primary outcomes:
measure: To evaluate the safety of using the combination of gemcitabine and bosutinib in the postoperative adjuvant treatment of patients with completely resected pancreatic cancer.
timeFrame: 8 weeks after the 6th patient is enrolled
measure: To estimate the median disease-free survival rate of patients with completely resected pancreatic cancer treated with this combination
timeFrame: 2 years after last patient is enrolled
Secondary outcomes:
measure: To determine the overall survival rates of patients with completely resected pancreatic cancer when treated postoperatively with the combination of gemcitabine and bosutinib
timeFrame: 2 years after last patient is enrolled
measure: To estimate both disease-free and overall survival at one and two years of patients with completely resected pancreatic cancer treated with this combination
timeFrame: 2 years after last patient is enrolled
Other outcomes:
Locations:
city: San Francisco
country: United States
facility: UCSF Helen Diller Family Comprehensive Cancer Center
state: California
city: Salt Lake City
country: United States
facility: Huntsman Cancer Institute, University of Utah
state: Utah
Study officials:
affiliation: University of California, San Francisco
name: Andrew H. Ko, MD
role: PRINCIPAL_INVESTIGATOR
References: